• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 13th August 2013

Special Issue of EJHE Examines Progress on Refinement of the EQ-5D

Just released online [open access] is a special issue of the European Journal of Health Economics on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Just released online [open access] is a special issue of the European Journal of Health Economics on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive Committee.

Just released online [open access] is a special issue of the European Journal of Health Economics[1] on the development of new research methods for the valuation of EQ-5D-5L. It is co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive Committee. 

The EQ-5D is arguably the best known and most commonly used generic measure of health status worldwide. Experience has provided evidence of both merits and limitations. One central concern is whether the three-level EQ-5D is sensitive enough to capture important aspects of health in certain disease areas. The EuroQol Group has undertaken an ambitious research and development program to address this, including the development of a five-level version of the EQ-5D, the EQ-5D-5L. This initiative is an opportunity to both advance methods for health state valuation and to offer a common protocol that can be followed in all countries.

Part of the EuroQol programme includes research aimed at overcoming well known problems and limitations with the “time trade off” (TTO) approach that is used to value the EQ-5D-5L. In particular, “lead” and “lag” time TTO approaches were investigated as potential methods for overcoming issues in valuing health states considered to be worse than being dead. The research also includes testing and evaluating preferences data for the EQ-5D-5L, which is more complex than its three-level predecessor for lay participants asked to value health states.

The papers in this issue report on this ambitious program of research. They draw together the findings from a multicountry pilot study to test an initial version of the study protocol and related experimentation with aspects of the methods in that protocol. Specifically, they compare the use of lead and lag time TTO; explore the effect on valuation of changing the length of duration of health states; examine the use of discrete choice methods in EQ-5D-5L valuation and explore the effect of different modes of data collection.

The research in this supplemental issue already has had an impact in refining and improving the methods in the Euroqol  Group’s final international protocol for producing EQ-5D-5L data sets. Studies based on this protocol are soon to be completed in Canada, China, England, The Netherlands and Spain; value sets for each country to be reported later this year. Value set studies are also about to commence in a range of other countries, including Germany, Japan, Hong Kong, Singapore, South Korea, Taiwan, Thailand and Uruguay. Other countries also have expressed interest. This fully documented research protocol will help ensure that studies undertaken meet a high standard. Moreover, the consistency of design and methods it promotes will allow for valid international comparisons of the EQ-5D-5L valuation data.

Research involving OHE’s Nancy Devlin and Koonal Shah is featured in several papers in this issue. For example, the article by Shah et al shows that the quality of TTO data clearly is affected by the mode of data collection: computer-assisted, one-on-one, interviewer-led interviews are superior to self-completion in a group setting. Nancy Devlin was involved in three of the studies on TTO: lead versus lag time, comparisons of lead/lag time to classic TTO approaches, and the use of visual aids in gathering reliable TTO valuations.

Previous research by Nancy and Koonal, available on this website as an OHE Research Paper:  

Download Devlin, N, Buckingham, K., Shah, K., Tsuchiya, A., Tilling, C., Wilkinson, G. and Van Hoot, B. (2010) A comparison of alternative variants of the lead and lag time TTO. Research Paper 10/02. London: Office of Health Economics.  [This has been published as: Devlin, N., Buckingham, K., Shah, K.K., Tsuchiya, A., Tilling, C., Wilkinson, G. and van Hout, B. (2013) A comparison of alternative variants of the lead and lag time TTO. Health Economics. 22(5), 517-532.]

See also Nancy’s recent presentations about the EuroQol Group and efforts worldwide to develop and apply EQ-5D measures on OHE’s SlideShare site. Her recent visits to Singapore and Sweden have been reported in this blog. 


[1] European Journal of Health Economics. (2013) 14(1 Suppl). Open access.
 
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!